Devendra Desai

Devendra Desai

Auto-generated profile, based on publicly available information

Devendra Desai

Division of Gastroenterology, P D Hinduja Hospital and Medical Research Centre, Mumbai, India

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2007 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
DDD. Desai
D. Desai
WFW. A. Faubion
W. A. Faubion
WSW. J. Sandborn
W. J. Sandborn

30 January 2022 in Intestinal Research
Verified
Journal Article
Open access
PDF file
ASArshdeep Singh
Arshdeep Singh
RMRamit Mahajan
Ramit Mahajan
SKSaurabh Kedia
Saurabh Kedia
ADAmit Kumar Dutta
Amit Kumar Dutta
AAAbhinav Anand
Abhinav Anand
ASAjit Sood
Ajit Sood
Inflammatory bowel disease (IBD), once considered a disease of the Western hemisphere, has emerged as a global disease. As the disease prevalence is on a steady rise, management of IBD has come under the spotlight. 5-Aminosalicylates, corticosteroids, immunosuppressive agents and biologics are the backbone of treatment of IBD. With the advent of biologics and small molecules, the need for surgery and hospitalization has decreased. However, economic viability and acceptability is an important determinant of local prescription patterns. Nearly one-third of the patients in West receive biologics as the first/initial therapy. The scenario is different in developing countries where biologics are used only in a small proportion of patients with IBD. Increased risk of reactivation of tuberculosis and high cost of the therapy are limitations to their use. Thiopurines hence become critical for optimal management of patients with IBD in these regions. However, approximately one-third of patients are intolerant or develop adverse effects with their use. This has led to suboptimal use of thiopurines in clinical practice. This review article discusses the clinical aspects of thiopurine use in patients with IBD with the aim of optimizing their use to full therapeutic potential.

6 November 2022 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
KUKhushboo G Upadhyay
Khushboo G Upadhyay
DDDevendra C Desai
Devendra C Desai
TATester F Ashavaid
Tester F Ashavaid
ADAlpa J Dherai
Alpa J Dherai

21 September 2011 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
DDDevendra Desai
Devendra Desai
SPSamir Patil
Samir Patil
ZUZarir Udwadia
Zarir Udwadia
SMShailendra Maheshwari
Shailendra Maheshwari
PAPhilip Abraham
Philip Abraham
AJAnand Joshi
Anand Joshi

1 March 2011 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MIMeghraj Ingle
Meghraj Ingle
ADAbhijit Deshmukh
Abhijit Deshmukh
DDDevendra Desai
Devendra Desai
PAPhilip Abraham
Philip Abraham
AJAnand Joshi
Anand Joshi
RMRanjit Mankeshwar
Ranjit Mankeshwar

30 April 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
ASAjit Sood
Ajit Sood
KKKirandeep Kaur
Kirandeep Kaur
RMRamit Mahajan
Ramit Mahajan
VMVandana Midha
Vandana Midha
ASArshdeep Singh
Arshdeep Singh
NRN. Sridhara Rao
N. Sridhara Rao
Background/Aims: The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India. Methods: A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed. Results: A total of 3,863 patients (mean age, 36.7 ± 13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n = 1,870, 57.9%) were from north, CD was more common in south (n = 348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female = 1.6:1). The commonest presentation of UC was moderately severe (n = 1,939, 60%) and E2 disease (n = 1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n = 229, 36.3%) inflammatory (n = 504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n = 26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south. Conclusions: The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care.